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Abstract
Background: CHI3L1 (YKL-40) is up-regulated in a variety of inflammatory conditions and cancers. We have previously 
reported elevated CHI3L1 concentration in the cerebrospinal fluid (CSF) of human and non-human primates with 
lentiviral encephalitis and using immunohistochemistry showed that CHI3L1 was associated with astrocytes.
Methods: In the current study CHI3L1 transcription and expression were evaluated in a variety of acute and chronic 
human neurological diseases.
Results: ELISA revealed significant elevation of CHI3L1 in the CSF of multiple sclerosis (MS) patients as well as mild 
elevation with aging. In situ hybridization (ISH) showed CHI3L1 transcription mostly associated with reactive astrocytes, 
that was more pronounced in inflammatory conditions like lentiviral encephalitis and MS. Comparison of CHI3L1 
expression in different stages of brain infarction showed that YKL40 was abundantly expressed in astrocytes during 
acute phases and diminished to low levels in chronic infarcts.
Conclusions: Taken together, these findings demonstrate that CHI3L1 is induced in astrocytes in a variety of 
neurological diseases but that it is most abundantly associated with astrocytes in regions of inflammatory cells.
Background
CHI3L1 (chitinase 3-like protein 1, human cartilage gly-
coprotein 39 (HC-gp39), YKL-40, gp38k, chondrex,
breast regression protein 39 (BRP-39)) is up-regulated in
inflamed tissues in ulcerative colitis, Crohn's disease,
rheumatoid arthritis, osteoarthritis, asthma, chronic
obstructive pulmonary disease (COPD) and liver cirrho-
sis, as well as in solid cancers [1-10]. Recently, we have
shown that CHI3L1 expression is induced in the CNS of
human and non-human primates with lentiviral encepha-
litis (HIV encephalitis (HIVE) and SIVE) [11]. The physi-
o logi ca l r ol e o f  CHI3L1 is not  known,  how eve r ,  it  has
been hypothesized to be involved with tissue remodeling
during inflammation. In a recent study, BRP-39 (the
mouse homologue of human CHI3L1) knockout mice
showed a blunted immune response to allergic sensitiza-
tion (e.g. decreased accumulation of dendritic cells in the
lungs, decreased IgE production, increased percentage of
apoptotic T-cells and macrophages in the bronchoalveo-
lar lavage) accompanied by reduced peribronchial fibrosis
and collagen content [12].
Previous studies have reported altered expression of
CHI3L1 in CNS disorders. Brain tissue homogenate stud-
ies have found increased CHI3L1 mRNA in schizophre-
nia, autism and Alzheimer's disease [13-15]. CSF studies
have also found elevated CHI3L1 in patients with puru-
lent meningitis and encephalitis [16]. In our previous
study, longitudinal analysis of CSF of SIV-infected
macaques showed that CHI3L1 concentrations in the
CSF increased between 2 to 8 weeks before terminal
encephalitis. Additionally, CSF levels were found to be
10-fold higher than plasma levels. Immunohistochemical
analysis showed that CHI3L1 was associated with astro-
cytes around microglial nodules in SIVE and occasional
activated macrophages/microglia. We have shown that
CHI3L1 can inhibit bFGF signaling through FGFR1 and
inhibit bFGF-induced axonal branching in hippocampal
neurons [11]. Thus, CHI3L1 potentially has the capacity
t o  m od u l a t e  n e u r o t r o p h i c  f a ct o r  as s oci a t ed  c h a n g e s  i n
the functionality, plasticity or regenerative ability of neu-
rons.
The current study was carried out to identify the spec-
trum of CHI3L1 expression in a variety of neurodegener-
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ative and neurological diseases, the cellular origin of CNS
CHI3L1, and in the case of brain infarction a comparison
between acute and chronic expression. We show that
CHI3L1 is elevated in CSF from patients with MS and to
a lesser extent with aging. CHI3L1 transcription is
induced in reactive astrocytes and is associated with local
neuroinflammation in acute and chronic diseases.
Methods
Human specimens
Ten de-identified CSF samples from each of AD, MS,
ALS, stroke and normal control patients were obtained
from the Human Brain and Spinal Fluid Resource Center
(UCLA, CA) and the Center for ALS Research at the Uni-
versity of Pittsburgh. Cortical tissue samples from three
cases of AD and schizophrenia, two cases of infarct and
Pick's disease and one case of MS and ALS were obtained
from the Human Brain and Spinal Fluid Resource Center
(UCLA, CA) and used for ISH and immunohistochemical
analyses. All human studies were approved by the corre-
sponding institutional review boards.
Pigtailed macaque tissues
Previously banked brains from four pigtailed macaques
(Macaca nemestrina) infected with SIVDeltaB670 viral
swarm (SIVdB670) that developed encephalitis and three
macaques that did not develop encephalitis were used for
in situ hybridization (ISH) and immunohistochemistry.
In situ hybridization
Sense and antisense CHI3L1 DNA templates containing
the T7 promoter were generated by PCR from the pUC57
vector (GenScript, Piscataway, NJ) containing the full
length YKL40 cDNA (NCBI Reference Sequence:
NM_001276.2). 35S-labeled RNA probes were generated
using MAXIscript in vitro transcription kit (Ambion,
Austin, TX). After removal of paraffin, cortical tissue sec-
tions from patients with MS, AD, Pick's disease, ALS,
stroke and schizophrenia and SIV-infected pigtailed
macaques were processed for in situ hybridization (ISH)
and then for immunohistochemistry. For ISH, tissue sec-
tions were microwave oven treated and then incubated in
hybridization buffer (1× HYB buffer, 0.6 M NaCl, 10%
dextran, 50 μg/ml tRNA, 0.1 M DTT) containing radiola-
beled CHI3L1 probe (50,000 cpm/μl) in 50°C over night.
The following day the tissue sections were washed and
processed for immunofluorescence. Tissue sections were
exposed to emulsion (Eastman Kodak company, Roches-
ter, NY) for 10 days in 4°C and then ISH signal was visual-
ized using D19 (Sigma-Aldrich, St. Louis, MO) and then
fixed in Rapid fix (Sigma-Aldrich, St. Louis, MO).
Immunofluorescence
Formalin-fixed, paraffin-embedded, 6-micrometer thick
tissue sections were deparaffinized in Histoclear
(National Diagnostics, Atlanta, GA) and rehydrated for 3
minutes in 100%, 95%, and 70% alcohol followed by PBS.
Endogenous peroxidase activity was inactivated by
immersing the section in 3% H2O2 for 20 minutes. Anti-
gen unmasking was performed using antigen retrieval
Citra® solution (BioGenex, San Ramon, CA). Tissue sec-
tions were blocked with protein blocking agent (Thermo,
Pittsburgh, PA) for 20 minutes. GFAP staining was per-
formed using polyclonal rabbit anti-human GFAP (1:500;
DAKO, Carpinteria, CA). Iba1 staining was performed
using rabbit anti-human Iba1 (1:500; Waco Chemicals,
Richmond, VA) and CHI3L1 staining was performed
using goat anti-human chitinase 3-like 1 (1:1000; R&D
systems, Minneapolis, MN). These staining were fol-
lowed by goat anti-rabbit Dylight 488 antibody (1:200;
Jackson ImmunoResearch Laboratories, West Grove, PA)
or mouse anti-goat biotin-conjugated antibody (1:200;
Jackson ImmunoResearch Laboratories, West Grove, PA).
Quantitation of in situ hybridization and 
immunofluorescence
F i v e  f i e l d s  f r o m  e a c h  c a s e  w e r e  c a p t u r e d  b y  c o n f o c a l
microscopy and analyzed for the number of ISH-positive
cells or ISH/IHC pixels per field (LSM 510, Carl Zeiss
MicroImaging, Inc., Thornwood, NY). Illumination was
provided by Argon (458, 477, 488, 514 nm, 30 mW),
HeNe (543 nm, 1 mW) lasers. Digital images were cap-
tured with LSM 510 version 4.2 (Zeiss).
Semi-quantitation of CHI3L1 in situ hybridization in infarct 
cases
Infarct presence or absence was established by a neuro-
pathologist (RLH), then infarct age was charachterized as
acute, subacute, or chronic based upon neuropathologi-
cal features seen on hematoxylin staining as previously
described [17]. Due to the focal nature of infarct pathol-
ogy a semi-quantitative scoring was performed by a neu-
ropathologist (CAW) blinded to clinical characteristics in
4 cases of acute infarct, 5 cases of subacute infarcts and 5
cases of chronic infarct. ISH scoring of CHI3L1 was
assigned a score from 0 to (++++) based on ISH intensity:
no siganl = 0, occasional positive cells = (+/-), weak signal
= (+), moderate signal = (++), strong signal = (+++) and
intense signal = (++++).
CHI3L1 enzyme-linked immunosorbent assay (ELISA)
CHI3L1 levels were determined, in duplicate, for all of
the CSF samples using the MicroVue CHI3L1 ELISA kit
from Quidel Corporation (San Diego, CA) according to
the manufacturer's protocol. Absorbance was measured
using a microplate reader (BioTek Instruments, Inc.,
Winooski, VT).
Statistical analysis
Average ± standard error (SEM) of CSF CHI3L1 concen-
trations from MS, AD, ALS, stroke patients and healthyBonneh-Barkay et al. Journal of Neuroinflammation 2010, 7:34
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young and aged controls were graphed. The Mann-Whit-
ney test was used to computes the statistical difference
between disease groups and control patients. CHI3L1
ISH and GFAP imuunohistochemistry pixels were cap-
tured by confocal microscopy from 5 random fields of
each of the SIVE, SIV, infarct, MS, AD, Pick's disease and
schizophrenia cases. Average pixels per filed were calcu-
lated and a linear regression was used to determine a cor-
relation between CHI3L1 pixel count and GFAP pixel
count.
Results
CSF YKL40 elevation with aging and acute and chronic 
neurological diseases
W e have previously observed elevated CHI3L1 concen-
tration in the CSF of SIV and HIV encephalitis [11] and
therefore wanted to assess its concentration in a broad
spectrum of human neurological diseases. CSF CHI3L1
levels of MS patients (age range: 25 to 58) were compared
to young healthy controls (age range: <40) and were
found to be significantly elevated (p = 0.0007) (Figure 1A,
Table 1). CSF samples from healthy aged controls, AD,
ALS and stroke showed statistically significant elevated
levels of CHI3L1 compared to young controls. However
there was no statistical difference between AD (age range:
59 to 86; median age: 75), ALS (age range: 32 to 74;
median age: 62.5) and stroke (age range: 60 to 89; median
age: 72) when these values were compared to healthy
older age-matched controls (age range: 60 to 70, median
age: 65). CSF CHI3L1 levels in healthy older people are
significantly higher then healthy young controls (p  =
0.0126) which implies that there is a modest but signifi-
cant increase of CSF CHI3L1 with aging (Figure 1B, Table
1).
CHI3L1 transcript is found predominantly in astrocytes in 
neurological diseases
Since our previously published in vitro studies demon-
strated that YKL40 was present in the supernatant of
macrophages and not astrocyte or neuronal cultures, we
were surprised to observe YKL40 staining localized with
astrocytes in regions of microglial nodules and occasional
activated macrophages/microglia in SIVE and HIVE. To
elucidate the cellular source of CHI3L1 in SIVE encepha-
litis we performed ISH combined with immunohis-
tochemistry. In order to validate the presence of CHI3L1
protein with its transcript we performed combined
CHI3L1 ISH with immunohistochemistry for CHI3L1 on
brain tissue from pigtailed macaques that developed
SIVE. This confirmed that the antibody against CHI3L1
stained the cells that expressed the CHI3L1 transcript
(Figure 2). The sense probe showed no significant hybrid-
ization (data not shown). Since the signal was more
robust with ISH and we wanted to identify the cellular
source of CHI3L1, we performed combined CHI3L1 ISH
with immunohistochemistry for GFAP as a marker for
astrocytes, NeuN as a marker of neurons and Iba1 as a
marker for microglia/macrophages. CHI3L1 transcripts
were shown to co-localize with GFAP staining (Figure
3A-C) but not with NeuN (Figure 3D-F) or Iba1 staining
(Figure 3G-I) in SIVE.
These results suggest that while macrophages can syn-
thesize YKL40 in vitro, in vivo CHI3L1 transcription is
most commonly associated with astrocytes. Since we
found elevated CHI3L1 levels in the CSF of a variety of
neurological and neurodegenerative diseases, we wanted
to study whether CHI3L1 expression is prevalent in
astrocytes in those conditions. Combined ISH with GFAP
staining was performed on sections from 4 cases of SIVE,
3 cases of SIV without encephalitis, AD and schizophre-
nia, 2 cases of Pick's disease and infarct and one case of
MS and ALS. The ISH signal showed robust CHI3L1
transcription in SIVE and MS, focal ISH signal in chronic
infarct cases while AD, ALS, Pick's disease and schizo-
phrenia showed a few scattered positive cells in some
areas while other areas were negative (Figure 4A).
CHI3L1 ISH signal and immunohistochemistry was co-
localized with GFAP staining in all the tested diseases
(e.g. AD (Figure 4B) and brain infarction (Figure 4D).
Table 1: CSF CHI3L1 levels in neurodegenerative diseases.




Healthy young controls (n = 12) <40 67-256 109
MS (n = 10) 28-58 (48) 152-697 281
Aged healthy controls (n = 7) 60-70 (65) 139-257 218
AD (n = 10) 59-86 (75) 153-1230 212
ALS (n = 10) 32-74 (62.5) 75-769 388
Stroke (n = 10) 60-89 (72) 160-1065 359
CSF samples from MS, AD, ALS, stroke and control patients were analyzed for CHI3L1 using the MicroVue CHI3L1 ELISA kit.Bonneh-Barkay et al. Journal of Neuroinflammation 2010, 7:34
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Confocal z-stack confirms that CHI3L1 (green) co-local-
izes with GFAP (red) staining as seen in yellow (Figure 4E
&4F). Pixel counts of CHI3L1 ISH signal correlated with
pixel counts of GFAP staining (r2 = 0.5637) indicative of a
correlation between CHI3L1 transcription and reactive
gliosis (Figure 4C).
In summary, CHI3L1 expression in MS, aging and
o t h e r  n e u r o l o g i c a l  d i s e a s e s  i s  m o s t l y  a s s o c i a t e d  w i t h
astrocytes. There is a correlation between CHI3L1 tran-
scription and GFAP staining which is indicative of reac-
tive gliosis. CHI3L1 transcription was more pronounced
in diseases with a more pronounced inflammatory nature
like encephalitis and MS.
YKL40 in acute and chronic stroke
The third aim of this study was to follow CHI3L1 expres-
sion in different stages of brain infarct. For that purpose
we analyzed CHI3L1 transcription in acute, subacute and
chronic brain infarction in humans. Combined ISH and
GFAP staining showed CHI3L1 expression in astrocytes
Figure 1 CSF CHI3L1 levels in neurodegenerative diseases and stroke. CSF samples from MS, AD, ALS, stroke and control patients were analyzed 
for CHI3L1 using the CHI3L1 ELISA kit. The Mann-Whitney test was used to evaluate group differences (*P < 0.05, **P < 0.001, ***P < 0.0001). CSF YKL-
40 levels in MS patients were significantly elevated compared to young, age-matched controls (A). While all neurodegenerative diseases and stroke 
show difference from young controls, AD, ALS and stroke patients do not show significant differences when compared to older age-matched controls 
(B).
Figure 2 CHI3L1 mRNA co-localizes with CHI3L1 immunohis-
tochemistry in SIVE. Six-μm-thick paraffin-embedded sections were 
hybridized with 35S-labeled RNA probe for CHI3L1 (B) followed by im-
munohistochemistry with for CHI3L1 (A) as described in Methods. 
CHI3L1 mRNA co-localizes with CHI3L1 immunohistochemistry, scale 
bar = 50 μm (C).
Figure 3 YKL-4 mRNA co-localizes with GFAP staining in SIVE. Six-
μm-thick paraffin-embedded sections were hybridized with 35S-la-
beled RNA probe for CHI3L1 (middle panels) followed by immunohis-
tochemistry with GFAP (A-C), NeuN (D-F) or Iba1 (G-I) as described in 
Methods. The right panels show the combined images of the ISH and 
immunohistochemistry, scale bar = 50 μm.Bonneh-Barkay et al. Journal of Neuroinflammation 2010, 7:34
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Figure 4 CHI3L1 mRNA in neurological diseases. Six-micrometer-thick paraffin-embedded sections from SIV encephalitis, SIV without encephalitis, 
AD, ALS, MS, Pick's disease, infarct and schizophrenia cases were hybridized with 35S-labeled RNA probe for CHI3L1 as described in Methods, scale bar 
= 100 μm (A). CHI3L1 ISH co-localized with GFAP in AD, scale bar = 20 μm (B) and brain infarction, scale bar = 50 μm (D). Higher magnification show 
co-localization in a single cell, scale bar = 10 μm (E). The panels to the right and on the top depict reconstructions from a confocal z-stack in xz and yz 
direction to confirm that CHI3L1 (green) co-localizes with GFAP (red) staining as seen in yellow (F). Five random fields from each case were captured 
by confocal microscopy and analyzed for CHI3L1 and GFAP pixels per field (C). Linear regression showed a positive correlation between CHI3L1 pixel 
count and GFAP pixel count (r2 = 0.5637; black circle SIVE, white circle SIV, black star MS, white triangle infarct, black diamond ALS, crossed square AD, 
gray circle Pick's disease, white circle Schizophrenia).Bonneh-Barkay et al. Journal of Neuroinflammation 2010, 7:34
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in the penumbra of the infarct that was more intense dur-
ing the acute phase of infarction. Subacute cases showed
less signal and chronic infarcts showed weak or no signal
above background (Table 2, Figure 5).
Discussion
In this study we found that CHI3L1 is expressed in astro-
cytes and is associated with reactive gliosis in different
neuropathological conditions particularly those associ-
ated with neuroinflammation. Therefore CHI3L1 could
potentially be explored as a biomarker for neuroinflam-
mation.
CHI3L1 expression in the neuroinflammatory model of SIVE
We have previously reported that CHI3L1 serves as a CSF
biomarker for the development of encephalitis after SIV
or HIV infection [11]. Our data showed a correlation
between the time-course of CHI3L1 concentration and
viral load in the CSF. In addition, we found a paradox that
CHI3L1 is released from macrophages in vitro but in vivo
CHI3L1 protein was in the soma of astrocytes in the
vicinity of microglial nodules. In this study we show that
CHI3L1 mRNA is expressed by reactive astrocytes sur-
rounding microglial nodules suggesting that mac-
rophages possibly through released inflammatory
mediators, can induce CHI3L1 expression in surrounding
astrocytes but not neurons. These findings suggest that
CHI3L1 found in the CSF in SIVE/HIVE could be derived
from reactive astrocytes. It has been shown by others that
differentiated macrophages do express CHI3L1 in vitro
and in vivo in peritumoral macrophages in small cell lung
cancer, in atherosclerotic plaques or in an asthma model
in mice [12,18,19]. Therefore, it is not clear why CHI3L1
transcription in the brain is less evident in activated tis-
sue macrophages/microglia. We hypothesize that YKL40
transcription by macrophages is inhibited soon after they
enter the brain and this may account for the differences
seen in other tissue pathologies. We are attempting to
further dissect this paradox with in vitro studies.
Table 2: CHI3L1 ISH in acute, subacute and chronic infarcts.
Condition Case No. Age and sex CHI3L1 ISH signal intensity
Acute infarct 1 58 female +++
2 61 male ++++
3 79 female ++++
4 85 male ++
Subacute infarct 1 56 female +++
28 1  f e m a l e 0
37 0  f e m a l e +
48 9  f e m a l e + / -
5 89 male +++
Chronic infarct 1 88 female +
2 74 male +
3 45 male ++
47 7  f e m a l e 0
58 8  f e m a l e 0
Six-μm-thick paraffin-embedded sections were hybridized with 35S-labeled RNA probe for CHI3L1 as described in Methods. ISH signal 
intensity was scored in 4 cases of acute infarct, 5 cases of subacute infarcts and 5 cases of chronic infarct (intense signal (++++), strong signal 
(+++), moderate signal (++), weak signal (+), occasional positive cells (+/-) and no signal (0)).
Figure 5 CHI3L1 transcription in acute, subacute and chronic in-
farcts. Six-micrometer-thick paraffin-embedded sections from acute 
(A), subacute (B) and chronic infarct (C) were hybridized with 35S-la-
beled RNA probe for CHI3L1 as described in Methods. Representative 
fields from acute, subacute and chronic infarcts were captured by con-
focal microscopy, scale bar = 50 μm.Bonneh-Barkay et al. Journal of Neuroinflammation 2010, 7:34
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CHI3L1 expression in stroke and neurodegenerative 
diseases
Previously, CHI3L1 expression was shown to be up-regu-
lated in inflammatory conditions, but apart from one
report of increased CHI3L1 mRNA in AD brain, there
were no data in the literature characterizing the cellular
source of CHI3L1 in neurodegenerative diseases. In this
study we found high CHI3L1 transcription in two highly
inflammatory diseases SIVE and MS. MS is a demyelinat-
ing disease associated with waxing and waning inflamma-
tion, gliosis and variable axon loss. CSF CHI3L1 levels
were significantly elevated in MS patients, however, HIV-
i n f ect ed  i n di vi d u a l  wi t h  h i g h  vi r a l  l oa d  s h o w ed  h i g h e r
CSF concentration consistent with the observation that
neuroinflammation in encephalitis is more robust than in
unselected MS. Comparing CSF concentration of
CHI3L1 in patients at different stages of MS might be
helpful in distinguishing active disease.
CHI3L1 transcript was also found in other neurodegen-
erative diseases like AD, ALS and Pick's disease as well as
stroke, although to a lesser extent than SIVE and MS. In
all cases, CHI3L1 was localized to astrocytes from which
we would conclude that CHI3L1 expression is a general
phenomena of reactive gliosis in response to neuroin-
flammation. Neuropathological astrocytosis not associated
with neuroinflammation (e.g. spontaneous spongiform
encephalopathy in rodents) is not associated with YKL40
expression (data not shown). This further emphasizes the
use of CHI3L1 as a potential marker for CNS inflamma-
tory conditions with its concentration reflecting a process
of reactive gliosis. CSF samples from these diseases show
increased CHI3L1 CSF levels compared to healthy young
adults. Perhaps not surprisingly, older healthy adults have
a very modest but significant elevation in CHI3L1 levels
consistent with the hypothesis that low-grade inflamma-
tory processes are induced in the aging brain.
CHI3L1 expression in schizophrenia
Recent studies showed increased CHI3L1 mRNA in the
hippocampus and prefrontal cortex of schizophrenic
patients [13,18]. Moreover, two genetic studies claimed
that variants in the promoter of CHI3L1 are associated
with susceptibility to schizophrenia [19,20]. However, a
more recent study failed to confirm a genetic association
between CHI3L1 and schizophrenia in Japanese and Chi-
nese populations [21]. Overall, our results showed only
occasional CHI3L1 positive cells in schizophrenia. That
the younger schizophrenic case (age 32) had almost no
CHI3L1 positive astrocytes while the other two cases
(ages 52 and 56) had more CHI3L1 positive astrocytes
raises the question whether there is a relationship
between CHI3L1 expression and schizophrenia or it is
just age-related reactive gliosis.
CHI3L1 expression in acute, subacute and chronic human 
brain infarction
Comparison of CHI3L1 transcription in acute, subacute
and chronic infarcts showed that there is focal and tem-
poral expression of CHI3L1 in astrocytes at the site of
injury. Maximal CHI3L1 induction starts at the acute
stages (3-5 days; ischemic changes in neurons visible,
prominent endothelium and early neutrophilic infiltrate;
no reactive astrocytes, no macrophages), continues at the
subacute stages (between 5 days to 4 weeks; numerous
foamy macrophages, some reactive astrocytes) and then
diminished at the chronic stages (more than 4 weeks; few
or no macrophages, abundant reactive astrocytes). These
differences in YKL-40 transcription in different stages of
pathology implies that acute inflammation induces
CHI3L1 expression in astrocytes proximal to the lesion
a n d  a s  i n f l a m m a t i o n  r e s o l v e s  C H I 3 L 1  e x p r e s s i o n  i s
diminished.
Conclusions
In summary, while the biological functions of CHI3L1 are
unclear, its expression is related to inflammation in a
variety of diseases, and in this study we show this is true
also in the brain. Paradoxically in the brain CHI3L1 syn-
t h e s i s  a p pea r s  t o  be  m o r e  as t r ocyt i c  t h a n  m a cr o p h a g e
based. The role of CHI3L1 in reactive astrogliosis is still
obscure, but from our previous study, it could potentially
be involved in growth factor mobilization from the extra-
cellular matrix and attenuation of their biological activi-
ties. Alternatively, a recent study by Shao et al showed
that CHI3L1 can directly induce cell signaling through
syndecan 1 and integrin ανβ3 and induce focal adhesion
kinase phosphorylation [22]. The BRP-39 knockout mice
showed reduced inflammation and fibrosis and therefore
one might speculate that the expression of CHI3L1 could
contribute to the survival of infiltrating inflammatory
cells thus prolonging their deleterious effects. This model
could be a valuable model to explore the role of CHI3L1
in neuroinflammation.
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